A landmark Harvard Medical School study confirmed semaglutide users face a significantly elevated risk of NAION — sudden potentially permanent vision loss. A Science Day is scheduled June 2 2026. Active lawsuits are being filed nationwide right now.
Warning: If you experienced sudden vision loss while taking Ozempic, Wegovy, or compounded semaglutide you may have a valid legal claim. Ophthalmologists are now urging the FDA to require a black box warning on these medications. Statute of limitations deadlines apply — do not wait.
NAION stands for Non-Arteritic Anterior Ischemic Optic Neuropathy. In plain language it is a sudden loss of blood flow to the optic nerve — the nerve that transmits everything your eye sees to your brain. When this nerve loses adequate blood flow the nerve tissue begins to die. Vision loss from NAION can range from a partial blind spot to near-total loss of vision in the affected eye and in the majority of cases the vision loss is permanent.
Researchers believe semaglutide may contribute to NAION through its effects on blood pressure and blood flow dynamics in the eye. GLP-1 receptor agonists significantly lower blood pressure. For individuals with anatomical predispositions the additional blood pressure lowering effect of semaglutide may push blood flow to the optic nerve below the threshold needed to sustain healthy tissue — particularly during sleep when pressure is naturally at its lowest.
A peer-reviewed study published in 2024 by Harvard Medical School researchers examined thousands of patients and found that individuals taking semaglutide had a statistically significant higher rate of NAION diagnosis compared to those taking other medications for the same conditions. A separate Danish registry study published in JAMA Ophthalmology reached similar conclusions using completely independent data. When two independent large-scale studies using different methodologies and patient populations reach the same conclusion the scientific community considers this convergent evidence substantially more reliable than a single study alone.
In 2026 a third study published in JAMA Ophthalmology found that semaglutide users were twice as likely to develop neovascular age-related macular degeneration — a separate condition that progressively destroys central vision. The accumulation of peer-reviewed evidence connecting semaglutide to vision harm is now substantial enough that ophthalmologists are formally calling on the FDA to require a black box warning on all semaglutide medications.
You do not need a formal NAION diagnosis in hand before submitting your case for review. Many patients experienced significant vision changes while on semaglutide but were never given a specific diagnosis. However any medical documentation that exists — including emergency room records ophthalmology visit notes or any formal diagnosis — strengthens your case significantly. If you experienced symptoms but never sought care a legal professional can advise on your specific situation. If you have not yet seen an ophthalmologist scheduling an appointment now and mentioning your semaglutide history is strongly recommended both for your health and your legal case.
Vision loss cases are among the highest-value claims in GLP-1 litigation. Cases involving permanent vision impairment — particularly in both eyes or the dominant eye — represent catastrophic harm to quality of life employment driving ability and independence. These factors drive substantially higher settlement values compared to conditions that resolve over time. For more detail see our settlement value page.
GLP-1 vision loss cases have been consolidated into their own MDL — MDL No. 3163 — created specifically for optic nerve injury claims. A Science Day is scheduled for June 2 2026 where both sides present scientific evidence to the judge. This is a critical milestone indicating the litigation is advancing toward bellwether trial selection. For full timeline see our monthly litigation update.
90 seconds. No cost. No obligation. A specialist contacts you within 24 hours.